Drug intelligence / Profile preview

Manifaxine

Development stage: Discontinued
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

Manifaxine (GW320659) is a highly selective neuronal norepinephrine and dopamine reuptake inhibitor developed by GlaxoSmithKline. It was investigated as a small molecule therapy for attention-deficit hyperactivity disorder (ADHD), obesity, and smoking cessation. The drug reached phase II clinical trials but development was discontinued for all indications. Manifaxine acts primarily by inhibiting the reuptake of norepinephrine and dopamine in the central nervous system[1][2][4][6].

Other names: manifaxinemanifaxinamanifaxinum

Targets

NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on Manifaxine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Manifaxine.

Explore the full profile